A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder

Journal of Clinical Psychopharmacology

Volumn 16, Issue 4, 1996, Pages 299-306

  Van Vliet, Irene M ^a,b   Den Boer, Johan A ^a   Westenberg, Herman G M ^a   Slaap, Bernard R ^a  

^a Academic Hospital Utrecht   (Netherlands)

^b Utrecht Universital Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BROFAROMINE; FLUVOXAMINE;

ADULT; AGORAPHOBIA; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HEADACHE; HUMAN; MALAISE; MALE; NAUSEA; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SLEEP DISORDER;

ADULT; ANTI-ANXIETY AGENTS; DOUBLE-BLIND METHOD; FEMALE; FLUVOXAMINE; HEADACHE; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; NAUSEA; PANIC DISORDER; PIPERIDINES; SEROTONIN UPTAKE INHIBITORS;

EID: 0030054456     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199608000-00005     Document Type: Article

References (59)

1. Eaton WW, Kessler RC, Wittchen HU, Magee WJ. Panic and panic disorder in the United States. Am J Psychiatry 1994;151:413-20.
2. Klein DF, Fink M. Psychiatric reaction patterns to imipramine. Am J Psychiatry 1962;119:432-8.
3. Modigh K. Antidepressant drugs in anxiety disorders. Acta Psychiatr Scand 1987;76[suppl 335]:57-71.
4. Liebowitz MR. Antidepressants in panic disorder. Br J Psychiatry 1989;155[suppl 6]:46-52.
5. Fontaine R. Clonazepam for panic disorder and agitation. Psychosomatics 1985;26[suppl 12]:13-6.
6. Liebowitz MR, Fyer AJ, Gorman JM, Campeas R, Levin A, Davies SR, Goetz D, Klein DF. Alprazolam in the treatment of panic disorder. J Clin Psychopharmacol 1986;6:13-20.
7. Evans L, Kenardy P, Hoey H. Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. Acta Psychiatr Scand 1986;73:40-53.
8. Hoehn-Saric R, McLeod DR, Hipsley A. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;5:321-6.
9. Woods S, Black D, Brown S, Potkin S. Fluvoxamine in the treatment of panic disorder in outpatients: a double-blind placebo controlled study. Neuropsychopharmacology 1994;10(suppl, part II):103.
10. den Boer JA, Westenberg HGM. Serotonin function in panic disorder a double-blind placebo-controlled study with fluvoxamine and ritanserin. Psychopharmacology 1990;102:85-94.
11. den Boer JA, Westenberg HGM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder, a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3:59-74.
12. Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50.
13. Johnston DG, Troyer IE, Whitstett SF. Clomipramine in the treatment of agoraphobic women. Biol Psychiatry 1988;25:101-4.
14. den Boer JA, Westenberg HGM, Kamerbeek WDJ, Verhoeven WMA, Kahn RS. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987;2:21-32.
15. Kahn RS, Westenberg HGM, Verhoeven WMA, Gispen-De Wied CC, Kamerbeek WDJ. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol 1987;2:33-45.
16. Judge A, Ohrstrom J, Manniche P, Christiansen P, Oehrberg S, Behnke K, Borup A, Severin B, Soegaard J, Calberg H. Paroxetine in the treatment of panic disorder. Eur Neuropsychopharmacol 1993;3:374-5.
17. Lecubier Y. A double blind placebo controlled study of paroxetine and clomipramine in the treatment of panic disorder. Poster presented at the 7th Congress of the Association of European Psychiatrists, Copenhagen, 1994.
18. Gorman JM, Liebowitz MR, Feyer AJ, Goetz P, Compaes RB, Feyer MJ, Davies SO, Klein DF. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987;7: 329-32.
19. Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Compaes RB, Schneider W, Klein DF. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990;10:119-21.
20. Solyom L, Solyom C, Ledwidge B. Fluoxetine in panic disorder. Can J Psychiatry 1991;36:378-80.
21. Humble M, Wistedt B. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders. Int Clin Psychopharmacol 1992;6[suppl 5]:21-39.
22. Pecknold JC, Luhte L, Scott-Fleury MH, Jenkins S. Gepirone and the treatment of panic disorder: an open study. J Clin Psychopharmacol 1993; 13:145-9.
23. Pohl R, Balon R, Yeragani VK, Gershon S. Serotonergic anxiolytics in the treatment of panic disorder, a controlled study with buspirone. Psychopathology 1989;22[suppl 1]:60-7.
24. Sheehan DV, Ray BA, Sheehan KH, Soto S. Is buspirone effective for panic disorder? J Clin Psychopharmacol 1990;10:3-11.
25. Sheehan DV, Ray BA, Trehan RR, Knapp EL Serotonin in panic disorder and social phobia. Int Clin Psychopharmacol 1993; 8[suppl 2]:63-77.
26. West ED, Dally PJ. Effect of iproniazid in depressive syndrome. BMJ 1959;1:1491-4.
27. Sargant W. Drugs in the treatment of depression. BMJ 1961;1:225-7.
28. Sargant W, Dally PJ. Treatment of anxiety states by antidepressant drugs. BMJ 1962;1A:6-9.
29. Kelly DGW, Frommer E, Mitchell-Heggs N, Sargant W. Treatment of phobic states with antidepressants: a retrospective study of 246 patients. Br J Psychiatry 1970;116:387-98.
30. Solyom L, Heseltine GFD, McClure DJ, Solyom C, Ledwidge B, Steinberg G. Behavioural therapy versus drug therapy in the treatment of phobic neurosis. Can Psychiatr Assoc J 1973; 18 :25-32.
31. Solyom C, Solyom L, LaPierre Y, Pecknold J, Morton L. Phenelzine and exposure in the treatment of phobias. Biol Psychiatry 1981;16:239-47.
32. Tyrer P, Candy J, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacology 1973;32:237-54.
33. Sheehan DV, Ballenger JC, Jacobson G. Treatment of endogenous anxiety with phobic, hysterical and hypochondric symptoms. Arch Gen Psychiatry 1980;37:51-9.
34. Sheehan DV, Claycomb JB, Surman OS. Comparison of phenelzine, imipramine, alprazolam and placebo in the treatment of panic attacks and agoraphobia Presented at the American Psychiatric Association Meeting, Los Angeles, 1984.
35. Amrein R, Allen SR, Vrasanic D, Stahl M. Antidepressant drug therapy: associated risk. J Neural Transm 1988;26[suppl]:73-86.
36. Da Prada M, Zurcher G, Wuttrich I, Haefely WE. The cheese effect and new reversible MAO-A inhibitors. J Neural Transm 1988; 26[suppl]:31-56.
37. Waldmeier PC, Snaith J. Brofaromine, a selective and reversible MAO-A inhibitor that concomitantly inhibits serotonin uptake. Proceedings ACNP Meeting, Puerto Rico 1992:15.
38. Berger P, Amering M, Dantendorfer K, Alf C, Kutzer M, Katchnig H. Moclobemide in panic disorder - an open dose finding study. Poster presented at the Vth World Congress of Biological Psychiatry, Florence, Italy, 1991.
39. Ozdaglar A, Wiedemann KI, Lauer CJ, Krieg JC. Brofaromine in the treatment of panic disorders. Pharmacopsychiatry 1989;22: 211-2.
40. Garcia-Borreguero D, Lauer CJ, Krieg JC, Holsboer F. Brofaromine in the treatment of panic disorders. Biol Psychiatry 1991; 29:2668.
41. Van Vliet IM, Westenberg HGM, den Boer JA. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine, a double-blind placebo-controlled study. Psychopharmacology 1993;112:483-9.
42. Bakish D, Saxena BM, Bowen R, D'Souza J. Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacology 1993;16[suppl2]:S77-S82.
43. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
44. Hamilton M. The assessment of anxiety states by rating, Br J Med Psychol 1959;32:50-5.
45. Marks IM, Matthews AM. Brief standard self-rating for phobic patients. Behav Res Ther 1979;17:263-7.
46. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
47. Mavissakalian M. The Fear Questionnaire: a validity study. Behav Res Ther 1989;24:83-5.
48. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale; preliminary report. Psychopharmacol Bull 1973;9:13-28.
49. Schneider W, Keller B, Degen PH. Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection. J Chromatogr 1989;4:275-82.
50. Guimaraes FS, Zuardi AW, Graeff FG. Effect of chlorimipramine and maprotiline on experimental anxiety in humans. J Psychopharmacol 1988;1:184-92.
51. Von Korff MR, Eaton WW, Keyl PM. The epidemiology of panic attacks and panic disorder: results of three community surveys. Am J Epidemiol 1985;122:970-80.
52. Gelder MG. Panic disorder: fact or fiction? Psychol Med 1989; 19:277-83.
53. Klerman GI, Weissman MM, Ouellette R. Panic attacks in the community. JAMA 1991;265:742-6.
54. Aronson TA. Is panic disorder a distinct diagnostic entity? J Nerv Ment Dis 1987;175:584-94.
55. Albus M, Lecrubier Y, Maier W, Buller R, Rosenberg R, Hippius H. Drug treatment of panic disorder, early response to treatment as a predictor of final outcome. Acta Psychiatr Scand 1990;82:359-65.
56. Rosenberg R, Bech P, Mellergard M, Ottosson JO. Alprazolam, imipramine and placebo treatment of panic disorder predicting therapeutic response. Acta Psychiatr Scand 1991;83[suppl 365]: 46-52.
57. Woodman CL, Noyes R Jr, Ballenger JC, Lydiard RB, Sievers G, Mihalco D. Predictors of response to alprazolam and placebo in patients with panic disorder. J Affect Disord 1994;30:5.
58. Black DW, Wesner RB, Gabel J, Bowers W, Monahan P. Predictors of short-term treatment response in 66 patients with panic disorder. J Affect Disord 1994;30:233-41.
59. Slaap BR, van Vliet IM, Westenberg HGM, den Boer JA. Phobic symptoms as predictors of non-response to drug therapy in panic disorder patients (a preliminary report). J Affect Disord 1995; 33:31-8.